🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

FDA approves new molluscum contagiosum treatment

EditorRachael Rajan
Published 05/01/2024, 22:08
© Reuters.
LGND
-

SAN DIEGO - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for treating molluscum contagiosum in adults and children one year and older. This marks the first FDA approval of a novel drug for molluscum infections, providing a significant advancement in the treatment of this highly contagious skin condition.

ZELSUVMI™ is the first topical prescription medication that can be self-applied at home, offering a new level of convenience for patients and caregivers. The approval is based on the results of two Phase 3 trials, which demonstrated the drug's ability to reduce lesion counts with a once-daily application and was well-tolerated by patients.

Dr. Mark D. Kaufmann, a Clinical Professor of Dermatology and Past President of the American Academy of Dermatology, expressed his anticipation for the availability of this new treatment, noting its breakthrough status. Similarly, Dr. Stephen W. Stripling, a pediatrician and molluscum researcher, highlighted the benefit of having an effective at-home treatment option over the traditional "wait and watch" approach.

Molluscum contagiosum affects approximately 6 million Americans each year, predominantly children, with up to 73% of affected children not receiving treatment. The condition is characterized by lesions that can spread the infection to others or different body areas if left untreated.

ZELSUVMI™, a nitric oxide releasing agent known for its antiviral properties, has an unknown mechanism of action in treating molluscum contagiosum. However, the efficacy of ZELSUVMI™ was established in the B-SIMPLE clinical program, involving 1,598 patients. The most common adverse reactions reported were application site reactions.

Ligand's CEO, Todd Davis, expressed pride in the team's achievement in completing the largest clinical program for molluscum and bringing this first-in-class medication to FDA approval. The company anticipates that ZELSUVMI™ will be commercially available in the United States during the second half of 2024.

This news is based on a press release statement from Ligand Pharmaceuticals Incorporated.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.